Poland· PL-100489760

Omjjara

A medicinal product containing momelotinibum, registered in Poland by GlaxoSmithKline Trading Services Limited.

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOmjjaraATC—REGISTER NO.PL-100489760PACKS LISTED1CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Momelotinibum
Manufacturer
GlaxoSmithKline Trading Services Limited
Country
Poland (PL)
ATC code
—
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991526184

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b1a58396-faca-48c4-a47e-08e97c9806d4
GET /v1/drugs/b1a58396-faca-48c4-a47e-08e97c9806d4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "150 mg",
  "packaging": "05909991526184 ¦ Rpz ¦ EU/1/23/1782/002 ¦ 152059\n1 butelka 30 tabl.",
  "substance": "Momelotinibum 150 mg",
  "common_name": "Momelotinibum",
  "pl_product_id": "100489760",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about momelotinibum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.